Abstract
INTRODUCTION
Helicobacter pylori (H. pylori) has been reported to be associated with many gastrointestinal diseases such as chronic gastritis, peptic ulcers, gastric carcinoma, and mucosa-associated lymphoid tissue lymphoma [1] [2] [3] . Until now, standard triple therapy consisting of a proton pump inhibitor and two broad-spectrum antibiotics, usually amoxicillin, clarithromycin or metronidazole, has been able to achieve eradication [3] [4] [5] . However, the Maastricht IV Consensus report recommended the careful choice of the antibiotic combination for treatment according to local H. pylori antibiotic resistance patterns due to multidrug resistance of H. pylori. For example, the concentrations of antibiotics for treatment of H. pylori infection were required at four times when H. pylori had local clarithromycin resistance [6] . Since antibiotic abuse had side effects and allowed development of resistance to antibiotics, alternative strategies have been proposed to counteract H. pylori infection. As an alternative approach, preservation of mucus from H. pylori attachment is emphasized because H. pylori infection disrupted the epithelial barrier which resulted in inflammation or cancer [7] . For example, dietary inhibitors such as lacto-oligosaccharide has been suggested as a solution for H. pylori infections [8] . Although oligosaccharides specific for the H. pylori lectins may potentially act as inhibitors of adhesion to mucus, their production in commercial amounts as antiadhesion therapeutic agents is still a problem [9, 10] . Here, we introduce a new N-acetylneuraminic acid (NANA) combined glycomacropeptide (GMP) which was made from milk serum hydrolysis protein powder as an anti-H. pylori agent. Wadström et al [11] reported that NANA derivative had an adhesion potential to H. pylori lectins and Hirmo et al [12] reported that milk glycoprotein had an anti-H. pylori effect. We designed a new material with NANA, GMP, and calcium (CaG-NANA), and anti-H. pylori activities of CaG-NANA were investigated both in vitro and in vivo. 
MATERIALS AND METHODS

H. pylori strain and experimental animals
Supply of CaG-NANA
CaG-NANA and each component of CaG-NANA were provided by MediNutrol (Kwangju, South Korea). As shown in Figure 1A , CaG-NANA was manufactured from calcium (Ca), GMP, and NANA by chelating and enzyme methods where the component concentrations were 5%, 85%, and 7%, respectively. For comparing each produced compound, we wrote abbreviated form as standard NANA (S-NANA), GMP linked NANA (G-NANA), and calcium chelated G-NANA (CaG-NANA).
High performance liquid chromatography for confirmation of NANA
For confirmation of NANA component, we analyzed CaG-NANA using high performance liquid chromatography (HPLC) method. HPLC analysis was performed using Agilent 1260 model equipped with a pump (G1311C), an auto sampler (G1329B), a column (G1316A), and a ultraviolet detector (G1314F), which was purchased from Agilent (Santa Clara, CA, United States). The condition of analysis was described in , and 1 × 10 6 colony forming units (CFU)/mL and cultured for 72 h. The minimal inhibitory concentration (MIC) was defined as the minimal concentration of CaG-NANA required for complete inhibition of H. pylori growth. The colonies were counted using image J (https://imagej.nih.gov/ij/) after 72 h incubation and the average number was calculated. Bactericidal activity was evaluated using time-kill curves with 0.5, 1.0 and 2.0 × MIC of CaG-NANA compared with the blank controls.
Experimental design in vivo
Mice (n = 40) were randomly divided into four groups: Blank control, H. pylori infected control, antibiotic treatment, and CaG-NANA treatment. H. pylori (1 × 10 9 /mL) was administered by gastric intubation to mice three times in a week except the blank control, and H. pylori infection was detected with gastric irrigation from randomly selected mice using an H. pylori detection test kit which was purchased from Pronto Dry (Brignais, France; Supple 1A). The antibiotic treatment was performed with a suspension of amoxicillin (12.33 mg/kg), metronidazole (164.40 mg/kg), and clarithromycin (205.54 mg/kg) which were equivalent to clinical administration (Dankook University hospital, Korea).
Treatments with CaG-NANA and each component including NANA, S-NANA, and G-NANA were performed by oral administration every day for 3 wk, and the experimental design is shown in Figure 2A .
Histological observation
The animals were deprived of feed but allowed free access to water for 24 h before sacrificed. At the end of sacrifice, blood was collected from mouse and gastric tissues were removed and fixed in 10% formalin. After fixation, tissues were processed and embedded in paraffin. The paraffin blocks were cut into 4 μm sections and stained with Harris' hematoxylin and eosin for histological observation under a microscope (BX51, Olympus, Miami, FL, United States).
Enzyme-linked immunosorbent assay
The expression levels of interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, and IL-10 in blood serum were determined using enzyme-linked immunosorbent assay (ELISA). Mouse ELISA kits were purchased from R&D Systems (Minneapolis, MN, United States). The assays were performed according to the manufacturer's instructions and repeated in triplicate.
Statistical analysis
Eradication rates were compared among groups by one-way analysis of variance (Kruskal-Wallis) and Dunn's multiple comparison test (GraphPad Software Inc., La Jolla, CA, United States). P < 0.05 was considered statistically significant.
RESULTS
Confirmation of NANA
As shown Figure 1B , the NANA component of CaG-NANA showed the same purity as standard NANA. 
Inhibitory effect of CaG-NANA on H. pylori in vitro
The bactericidal effects of CaG-NANA and each component against H. pylori were assessed in vitro. We described previously that CaG-NANA is composed of NANA, GMP and calcium, thus we tested the antibacterial effects of every component used in CaG-NANA synthesis. As shown in Figure 1 , S-NANA, G-NANA and CaG-NANA had an anti-bacterial effect ( Figure 1D , E and F) whereas GMP and GMP with calcium (CaG) had no activity in the colony forming assay ( Figure 1B and C) . This result indicated that only NANA included compound had anti-bacterial activity.
Inhibitory effect of CaG-NANA on H. pylori in vivo
For the in vivo study, we divided mice into four groups and 1 × 10 9 /mL CFU of H. pylori was administered into mice three times for one week except the negative group. H. pylori infection was confirmed by gastric irrigation using an H. pylori detection test kit (Pronto Dry). After confirmation, treatments with antibiotics, CaG-NANA and its components were orally administered every day for 3 wk. The doses of antibiotics were described in the "Material and Methods" section ( Figure  3A) . The doses of CaG-NANA and its components were fixed at 0.5% (v/w). We followed the mouse weight after treatment. As shown in Figure 3B , mouse weight was decreased in the S-NANA and H. pylori positive control groups. From this result, S-NANA was considered to have toxicity at 0.5% of concentration.
Next, we observed the gastric mucus layer of mice. The majority of the H. pylori population reside in the mucus which binds the organisms via specific interactions such as pathogen adherence. Normal gastric mucosa has a uniform surface epithelium ( Figure 4A) , whereas H. pylori infected gastric mucosa has an irregular outline of the epithelium layer along with neutrophil and macrophage infiltrations ( Figure 4B ). In addition, bacterial attachment is mediated by outer membrane adhesions that bind to glycoconjugates present in the gastric mucus layer, lining the surface epithelium of the gastric mucosa in the H. pylori infected group. As shown in Figure 4C , the antibiotic treatment group had decreased infiltration of macrophages and adhesion of H. pylori colonization, however, the destruction of surface epithelium layers was also observed. Meanwhile, every NANA including group showed uniformed surface epithelium layers. Interestingly, many macrophages and neutrophils were observed in the S-NANA treatment , and 1 × 10 6 CFU/mL and cultured for 72 h. The minimal inhibitory concentration (MIC) was defined as the minimal concentration of materials required for complete inhibition of H. pylori growth. Bactericidal activity was evaluated using time-kill curves with 0.5, 1.0 and 2.0 × MIC of CaG-NANA compared with blank controls. All experiments were performed three times and significance was set at group ( Figure 4D ). The damage to surface epithelium in the antibiotics treatment group and inflammation observed in the S-NANA treatment group might be related to mouse weight loses. Both the G-NANA and CaG-NANA treatment groups showed the detachment of H. pylori colonization without any damage to surface epithelium or inflammation ( Figure 4E and F) .
We also assessed the levels of IL-1β, IL-6, TNF-α, and IL-10 in blood by ELISA. PBS was used as a control because every compound was dissolved in PBS. Both of S-NANA and CaG-NANA showed a potent ability to decrease inflammatory cytokines. The level of IL-1β was reduced from 7.6 ng/mL to 0.8 ng/mL after S-NANA treatment and 2.36 ng/mL after CaG-NANA treatment ( Figure 5A ). The level of IL-6 was remarkedly decreased from 113.4 ng/mL to 33.5 ng/mL after S-NANA treatment and 1.26 ng/mL after CaG-NANA treatment ( Figure  5B ). The level of TNF-α was also reduced to 8.21 ng/mL after S-NANA treatment and 1.44 ng/mL after CaG-NANA treatment ( Figure 5C) . Meanwhile, the level of IL-10 was reduced only in the CaG-NANA treatment group from 7.62 ng/mL to 6.3 ng/mL ( Figure 5D ).
DISCUSSION
The anti-H. pylori effects of antibiotic formulas have been investigated, but the findings are limited by varying drug quality and sources, as well as the numerous and complicated components of formulas. Thus, it has been suggested that dietary inhibitors may be a solution for certain infections as an alternative approach [8] .
Eradication of H. pylori has remained difficult for reasons that lie in the biology and environment of the organism. H. pylori populations colonize epithelial cells that line the antrum of the stomach and survive in the acidic environment [13] . Most anti-microbial agents are poorly secreted in the gastric mucosa because of the stomach environment [14] , and the residues expressed on H. pylori enable specific binding to the mucus layers. Thus, CaG-NANA was excogitated to overcome the acidic environment of the stomach and have bactericidal activity by interrupting glycol-conjugation of H. pylori on the mucosa.
CaG-NANA, a compound of N-acetylneuraminic acid with calcium combined glycomacropeptide, demonstrated an anti-bacterial effect against H. pylori. We manufactured CaG-NANA as a dietary inhibitor against H. pylori; NANA was demonstrated as an H. pylori adhesion blocker [9, 15, 16] , glycomacropeptide was used for modulating the acidic phase of the stomach, and calcium was inserted for improvement as functional food. NANA content in CaG-NANA was evaluated compared to S-NANA by HPLC, which confirmed its content and purity ( Figure 1B) . CaG-NANA at concentrations > 0.25% regulated the population of H. pylori in vitro. S-NANA also decreased the population of H. pylori in vitro ( Figure  2D) ; however, S-NANA resulted in a severe weight loss in vivo (Figure 3B ), which demonstrated that S-NANA treatment only had negative utility. Meanwhile, G-NANA and CaG-NANA had bactericidal and anti-adhesion effects on glyco-conjugation of the mucosa without toxicity. Bacterial attachment is mediated by outer membrane adhesions that bind to glycoconjugates present in the gastric mucus layer and lining the surface epithelium of the gastric mucosa [17] . H. pylori is also known to induce inflammatory response that includes the up-regulation of pro-inflammatory cytokines. CaG-NANA exerted a down-regulatory effect on pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α and IL-10. Reduction of pro-inflammatory cytokines induced by H. pylori is responsible for the recruitment of macrophages and neutrophils in the lamina propria. CaG-NANA exerted an antagonistic effect against H. pylori, which is an anti-microbial effect via different mechanisms from those of antibiotics.
This study suggests that it is possible to decrease the number of H. pylori or its activation in the stomach through a regular ingestion of N-acetylneuraminic acid containing glycomacropeptide as dietary products. Moreover, CaG-NANA is a complex compound which can be manufactured in large scale at a low cost under good manufacturing practice (GMP). In conclusion, the anti-H. pylori effects of CaG-NANA were confirmed both in vitro and in vivo, which provided experimental support for future human trials.
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